Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MERCK SENIOR VP LEWENT ADDS PUBLIC AFFAIRS, SCOLNICK ADDS MANUFACTURING

Executive Summary

MERCK SENIOR VP LEWENT ADDS PUBLIC AFFAIRS, SCOLNICK ADDS MANUFACTURING in redelegations of senior & exec oversight related to the departure of Exec VP John Zabriskie to Upjohn. Judy Lewent, chief financial officer, will take on the senior management role in Merck's public affairs functions, including Washington lobbying activities. Merck's worldwide manufacturing operations will be headed by a new president of manufacturing, Bernard Kelley, who will report to Exec VP Edward Scolnick. The public affairs and manufacturing functions were the two primary responsibilities previously filled by Zabriskie as an exec VP. The third component of Zabriskie's position, oversight of the specialty chemicals group, the Kelco Division, was given to Exec VP Francis Spiegel, who will continue to be responsible for strategic planning, the external growth program, licensing, human resources, internal auditing and joint ventures. Scolnick, a longtime Vagelos protege, has been the most visible of the executive group outside the company. He has appeared frequently at public appearances with Vagelos before the financial community and accompanied Vagelos to the unveiling of the National AIDS Drug Development Task Force Nov. 30. Lewent has received attention as one of the high-ranking women execs at a major U.S. company. The new position may further that visibility. She recently appeared as a witness at a Senate Labor & Human Resources Committee hearing chaired by Sen. Dodd (D-Conn.) on the impact of the health reform bill on the drug industry ("The Pink Sheet" Nov. 22, p. 6) Treasurer Michael Atieh assumes the direct responsibility for public affairs and government relations, moving to VP-public affairs effective Jan. 1. Atieh succeeds Albert Angel, who is retiring at the end of the year. Atieh formerly headed Merck's Washington office before returning to corporate headquarters as treasurer. Under Lewent and Atieh, Merck has been more aggressive in blending financial information and political positioning. Manufacturing president Kelley is moving up from a senior VP position in the manufacturing division. Kelley joined Merck in 1967 as an engineer, and since then has held positions in quality control, pharmaceutical production, packaging operations, technical services and materials management. In 1991, he became senior VP-administration, planning and quality for the manufacturing division, and in August 1993 was named senior VP- operations. Kelley will report to Scolnick, who holds the positions of exec VP-science and technology and president of Merck Research Labs. Scolnick will also continue to have responsibility for the Merck AgVet Division and Corporate Computer Resources.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS023766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel